Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts hold a “Moderate Buy” consensus on Ironwood Pharmaceuticals, with two buy ratings, one strong-buy rating and four hold ratings. The average 12-month price target is $6.23.
• Company insiders recently reduced their holdings, including Ronald Silver’s sale of 127,890 shares and Julie Mchugh’s sale of 21,571 shares. Several institutional investors also initiated or increased positions.
• Ironwood reported quarterly EPS of $0.31, slightly below the $0.32 consensus, while revenue of $113.04 million missed estimates of $114.84 million. The stock opened at $4.29, with a 12-month range of $1.01 to $5.78.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has been given an average rating of "Moderate Buy" by the seven analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.2333.

IRWD has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Zacks Research downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Finally, Weiss Ratings raised Ironwood Pharmaceuticals from a "hold (c-)" rating to a "hold (c+)" rating in a research note on Friday.

Insider Activity

In other news, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total transaction of $578,062.80. Following the completion of the sale, the insider owned 313,680 shares in the company, valued at approximately $1,417,833.60. This trade represents a 28.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Julie Mchugh sold 21,571 shares of the business's stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total value of $80,459.83. Following the transaction, the director directly owned 250,749 shares of the company's stock, valued at $935,293.77. The trade was a 7.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 9.30% of the company's stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC raised its position in shares of Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company's stock valued at $25,000 after buying an additional 3,406 shares in the last quarter. LSV Asset Management purchased a new position in Ironwood Pharmaceuticals in the fourth quarter worth $30,000. Captrust Financial Advisors bought a new position in Ironwood Pharmaceuticals in the second quarter valued at $32,000. Jump Financial LLC bought a new position in Ironwood Pharmaceuticals in the fourth quarter valued at $34,000. Finally, DGS Capital Management LLC bought a new position in Ironwood Pharmaceuticals in the fourth quarter valued at $35,000.

Ironwood Pharmaceuticals Stock Performance

IRWD stock opened at $4.29 on Monday. The firm has a 50 day moving average of $4.08 and a 200-day moving average of $3.91. Ironwood Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $5.78. The firm has a market capitalization of $708.88 million, a P/E ratio of 5.57 and a beta of 0.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.The firm had revenue of $113.04 million for the quarter, compared to the consensus estimate of $114.84 million. Sell-side analysts predict that Ironwood Pharmaceuticals will post 1.04 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company's flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.